Table 3.
Pre-Infection data and post-COVID symptoms according to the ACE2 rs2074192 Polymorphism Genotype (n = 290).
| C/C (n = 131) | C/T (n = 66) | T/T (n = 93) | p Value | |
|---|---|---|---|---|
| Age, mean (SD), years | 56.1 (13.0) | 56.0 (13.0) | 57.5 (12.5) | 0.604 |
| Gender, female n (%) | 49 (37.4%) | 65 (98.5%) | 31 (33.3%) | <0.001 |
| Weight, mean (SD), kg. | 83.1 (16.3) | 74.5 (16.3) | 82.3 (16.4) | 0.001 |
| Height, mean (SD), cm. | 169 (9.5) | 164 (7.5) | 168 (9.0) | 0.001 |
| Number co-morbidities, mean (SD) | 1.4 (1.1) | 1.3 (0.9) | 1.2 (0.9) | 0.489 |
| Medical co-morbidities, n (%) | ||||
| Hypertension | 47 (35.9%) | 20 (30.3%) | 34 (36.5%) | 0.647 |
| Diabetes | 9 (6.6%) | 7 (10.6%) | 14 (15.0%) | 0.184 |
| Cardiovascular Diseases | 12 (9.1%) | 2 (3.0%) | 7 (7.5%) | 0.306 |
| Asthma | 16 (12.9%) | 9 (13.6%) | 7 (7.5%) | 0.154 |
| Obesity | 47 (35.9%) | 20 (30.3%) | 23 (24.7%) | 0.302 |
| Chronic Obstructive Pulmonary Disease | 2 (1.5%) | 0 (0.0%) | 4 (4.3%) | 0.153 |
| Number post-COVID symptoms, mean (SD) | 2.8 (1.9) | 3.3 (1.9) | 2.9 (1.9) | 0.222 |
| Post-COVID symptoms, n (%) | ||||
| Fatigue | 79 (60.3%) | 45 (68.2%) | 58 (62.4%) | 0.811 |
| Pain Symptoms | 52 (39.7%) | 34 (51.5%) | 30 (32.2%) | 0.045 |
| Memory Loss | 34 (25.9%) | 21 (31.8%) | 37 (39.8%) | 0.217 |
| Hair Loss | 26 (19.8%) | 26 (39.4%) | 25 (26.0%) | 0.06 |
| Concentration Loss | 22 (16.8%) | 12 (18.2%) | 10 (10.7%) | 0.391 |
| Cognitive Blunting-Brain Fog | 17 (13.0%) | 14 (21.2%) | 10 (10.7%) | 0.207 |
| Dyspnoea | 15 (11.4%) | 10 (15.1%) | 15 (16.1%) | 0.641 |
| Ocular Disorders | 19 (14.5%) | 10 (15.1%) | 12(12.9%) | 0.915 |
| Anosmia/Hyposmia | 12 (9.2%) | 6 (9.1%) | 11 (11.8%) | 0.809 |
| Skin Rashes | 13 (9.9%) | 10 (15.1%) | 14 (15.1%) | 0.498 |
| Gastrointestinal Disorders | 16 (12.2%) | 5 (7.6%) | 6 (6.5%) | 0.310 |
| Ageusia/Hypogeusia | 9 (6.9%) | 6 (9.1%) | 5 (5.4%) | 0.681 |
| Days at hospital, mean (SD) | 7.5 (6.5) | 7.2 (6.8) | 9.8 (12.2) | 0.08 |